Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Rating) has earned an average rating of "Moderate Buy" from the ten analysts that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $39.67.
据MarketBeat报道,Cerevel治疗控股公司(纳斯达克:CERE-GET评级)目前跟踪该股的十位分析师的平均评级为“中等买入”。两名分析师对该股的评级为持有,七名分析师对该公司的评级为买入。在过去一年追踪该股的券商中,1年目标价的平均水平为39.67美元。
Several research analysts have recently weighed in on the stock. Mizuho dropped their target price on shares of Cerevel Therapeutics from $32.00 to $28.00 and set a "neutral" rating on the stock in a research report on Thursday, November 10th. JPMorgan Chase & Co. dropped their target price on shares of Cerevel Therapeutics from $49.00 to $40.00 and set an "overweight" rating on the stock in a research report on Tuesday, December 6th. The Goldman Sachs Group raised their price target on shares of Cerevel Therapeutics from $24.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, September 21st. Wells Fargo & Company started coverage on shares of Cerevel Therapeutics in a report on Monday, September 26th. They set an "overweight" rating and a $38.00 price target for the company. Finally, HC Wainwright decreased their price target on shares of Cerevel Therapeutics from $50.00 to $48.00 and set a "buy" rating for the company in a report on Wednesday, November 9th.
几位研究分析师最近对该股进行了加码。瑞穗在11月10日周四的一份研究报告中将Cerevel Treeutics的股票目标价从32.00美元下调至28.00美元,并将该股的评级定为中性。12月6日,摩根大通在一份研究报告中将Cerevel Treateutics的股票目标价从49.00美元下调至40.00美元,并将该股的评级定为“增持”。在9月21日星期三的一份报告中,高盛夫妇将Cerevel治疗公司的股票目标价从24.00美元上调至28.00美元,并给予该股“中性”评级。富国银行公司在9月26日星期一的一份报告中开始报道Cerevel治疗公司的股票。他们为该公司设定了“增持”评级和38.00美元的目标价。最后,HC Wainwright将Cerevel治疗公司的股票目标价从50.00美元下调至48.00美元,并在11月9日星期三的一份报告中为该公司设定了“买入”评级。
Insider Buying and Selling
内幕买卖
In related news, CEO N Anthony Coles sold 50,000 shares of the business's stock in a transaction on Friday, December 9th. The shares were sold at an average price of $26.67, for a total transaction of $1,333,500.00. Following the transaction, the chief executive officer now owns 2,704 shares of the company's stock, valued at $72,115.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.30% of the stock is currently owned by insiders.
在相关新闻中,首席执行官N安东尼·科尔斯在12月9日星期五的一次交易中出售了50,000股该公司的股票。这些股票的平均价格为26.67美元,总成交额为1,333,500.00美元。交易完成后,这位首席执行官现在拥有2704股公司股票,价值72,115.68美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可在此超链接。4.30%的股份目前由内部人士持有。
Institutional Investors Weigh In On Cerevel Therapeutics
机构投资者看好Cerevel Treeutics
Cerevel Therapeutics Trading Down 1.3 %
Cerevel治疗公司股价下跌1.3%
Shares of NASDAQ:CERE opened at $32.79 on Friday. The company has a market cap of $5.13 billion, a PE ratio of -15.39 and a beta of 1.47. The company's 50-day moving average price is $29.13 and its 200 day moving average price is $29.12. Cerevel Therapeutics has a fifty-two week low of $19.86 and a fifty-two week high of $41.46. The company has a quick ratio of 16.64, a current ratio of 16.64 and a debt-to-equity ratio of 0.56.
上周五,纳斯达克股价开盘报32.79美元。该公司市值为51.3亿美元,市盈率为-15.39,贝塔系数为1.47。该公司的50日移动均线价格为29.13美元,200日移动均线价格为29.12美元。Cerevel Treateutics的股价为52周低点19.86美元,52周高点为41.46美元。该公司的速动比率为16.64,流动比率为16.64,债务权益比为0.56。
Cerevel Therapeutics (NASDAQ:CERE – Get Rating) last released its quarterly earnings results on Tuesday, November 8th. The biotechnology company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.04). Sell-side analysts anticipate that Cerevel Therapeutics will post -2.36 earnings per share for the current year.
Cerevel Treateutics(纳斯达克:CEERE-GET评级)最近一次发布季度收益报告是在11月8日(星期二)。这家生物技术公司公布了该季度每股收益(0.66美元),低于分析师普遍预期的(0.62美元)和(0.04美元)。卖方分析师预计,Cerevel治疗公司本年度的每股收益将达到2.36美元。
Cerevel Therapeutics Company Profile
Cerevel治疗公司简介
(Get Rating)
(获取评级)
Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety.
Cerevel治疗控股公司是一家临床阶段的生物制药公司,致力于神经科学疾病的各种疗法的开发。它正在开发emraclidine,一种正变构调节剂(PAM),正处于治疗精神分裂症的1b期临床试验;以及Darigabat,一种PAM,正处于第二阶段的概念验证试验,用于癫痫或局灶性癫痫的耐药局灶性发作患者,以及治疗急性焦虑的第一阶段试验。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Cerevel Therapeutics (CERE)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here's Why
- Carvana Stock Rally, Here's What You Need to Know
- 免费获取StockNews.com关于Cerevel治疗的研究报告(CERE)
- MarketBeat:回顾中的一周01/09-01/13
- 摩根大通破产,银行为衰退做好准备
- 为什么Bed Bath&Beyond的股价上涨了261%?
- Roku股价走势,原因如下
- Carvana Stock Rally,这是你需要知道的
Receive News & Ratings for Cerevel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerevel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Cerevel Treateutics Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Cerevel Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。